Evidence map›Paper›PMID 28187452›Full record

ArticleOncotarget2017

PIGN gene expression aberration is associated with genomic instability and leukemic progression in acute myeloid leukemia with myelodysplastic features.

Emmanuel K Teye, Abigail Sido, Ping Xin, Niklas K Finnberg, Prashanth Gokare, Yuka I Kawasawa, Anna C Salzberg, Sara Shimko, Michael Bayerl, W Christopher Ehmann and 9 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Tumor Hypoxia Drives Genomic Instability.Frontiers in cell and developmental biology · 2021
    Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 4 institutions in 1 country.

Emmanuel K TeyePenn State Hershey Cancer Institute and Department of Medicine, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Abigail SidoPenn State Hershey Cancer Institute and Department of Medicine, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Ping XinPenn State Hershey Cancer Institute and Department of Medicine, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Niklas K FinnbergDepartment of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Prashanth GokareDepartment of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Yuka I KawasawaInstitute for Personalized Medicine and Departments of Pharmacology, Biochemistry and Molecular Biology, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Anna C SalzbergInstitute for Personalized Medicine and Departments of Pharmacology, Biochemistry and Molecular Biology, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Sara ShimkoPenn State Hershey Cancer Institute and Department of Medicine, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Michael BayerlDepartment of Pathology, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
W Christopher EhmannPenn State Hershey Cancer Institute and Department of Medicine, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
David F ClaxtonPenn State Hershey Cancer Institute and Department of Medicine, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Witold B RybkaPenn State Hershey Cancer Institute and Department of Medicine, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Joseph J DrabickPenn State Hershey Cancer Institute and Department of Medicine, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Hong-Gang WangDepartment of Pediatrics, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Thomas AbrahamDepartment of Neural and Behavioral Science and the Microscopy Imaging Facility, Pennsylvania State University, Hershey, Pennsylvania, USA.
Wafik S El-DeiryDepartment of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Robert A BrodskyDivision of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Raymond J HohlPenn State Hershey Cancer Institute and Department of Medicine, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Jeffrey J PuPenn State Hershey Cancer Institute and Department of Medicine, Penn State University College of Medicine, Hershey, Pennsylvania, USA.
Penn State Milton S. Hershey Medical Center · USFox Chase Cancer Center · USPennsylvania State University · USJohns Hopkins Medicine · US

Funding

Tissue Repository and Animal Models CoreP01CA171983 · NCI · UNIVERSITY OF VIRGINIA · PI CHALFANT, CHARLES E. · 2013 to 2024
$19.9M
NCI NIH HHS P01 CA171983
6 · The paper itself

Abstract

Previous studies have linked increased frequency of glycosylphosphatidylinositol-anchor protein (GPI-AP) deficiency with genomic instability and the risk of carcinogenesis. However, the underlying mechanism is still not clear. A randomForest analysis of the gene expression array data from 55 MDS patients (GSE4619) demonstrated a significant (p = 0.0007) correlation (Pearson r =-0.4068) between GPI-anchor biosynthesis gene expression and genomic instability, in which PIGN, a gene participating in GPI-AP biosynthesis, was ranked as the third most important in predicting risk of MDS progression. Furthermore, we observed that PIGN gene expression aberrations (increased transcriptional activity but diminished to no protein production) were associated with increased frequency of GPI-AP deficiency in leukemic cells during leukemic transformation/progression. PIGN gene expression aberrations were attributed to partial intron retentions between exons 14 and 15 resulting in frameshifts and premature termination which were confirmed by examining the RNA-seq data from a group of AML patients (phs001027.v1.p1). PIGN gene expression aberration correlated with the elevation of genomic instability marker expression that was independent of the TP53 regulatory pathway. Suppression/elimination of PIGN protein expression caused a similar pattern of genomic instability that was rescued by PIGN restoration. Finally, we found that PIGN bound to the spindle assembly checkpoint protein, MAD1, and regulated its expression during the cell cycle. In conclusion, PIGN gene is crucial in regulating mitotic integrity to maintain chromosomal stability and prevents leukemic transformation/progression.

Indexed as

Gene Expression Regulation, LeukemicGenomic InstabilityBone MarrowCell Cycle ProteinsCell Transformation, NeoplasticComputational BiologyDisease ProgressionExonsFemaleGene Expression ProfilingGene Knockdown TechniquesGenes, p53HumansIntronsLeukemia, Myeloid, AcuteMaleCell Cycle ProteinsMAD1L1 protein, humanNuclear ProteinsPhosphotransferasesPIGN protein, humanAML with myelodysplasia-related changes (AML-MRC)genomic instabilityleukemogenesisMDSPIGN gene expression aberration

Identifiers

PMID28187452
PMCPMC5444711
OpenAlexW2586087252

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.